- Home
- GSHD vs XNCR Comparison
GSHD vs XNCR Comparison
Compare GSHD & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | XNCR |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GSHD | XNCR |
|---|---|---|
| Price | $46.52 | $25.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $72.50 | $22.33 |
| AVG Volume (30 Days) | 287.0K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | $125,576,000.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $18.53 | $4.80 |
| P/E Ratio | $49.71 | ★ N/A |
| Revenue Growth | ★ 16.15 | 13.65 |
| 52 Week Low | $33.68 | $10.24 |
| 52 Week High | $79.85 | $30.61 |
Technical Indicators
Market Signals| Indicator | GSHD | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 26.74 | 54.25 |
| Support Level | $40.71 | $11.05 |
| Resistance Level | $56.00 | $30.61 |
| Average True Range (ATR) | 3.63 | 1.09 |
| MACD | -1.76 | -0.33 |
| Stochastic Oscillator | 2.86 | 35.41 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.